2014-11-26 23:03:10 UTC

CGH Podcast November 2014: Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis

A study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to co-author Dr. James Lewis of the Perelman School of Medicine at the University of Pennsylvania; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

 

 

Osterman MT, Aberra FN, Cross R. Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology & Hepatology 2014; November 12(11): 1887–1893.e3
Abstract

 

 

 

Duration: 15.20m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

 

 

More on Ulcerative Colitis

Open for public comment: management of mild-moderate UC guideline

April 24, 2018

Review and submit your feedback by Monday, May 21.

Leading patient, professional organizations announce funding to improve communications, address IBD shared decision-making

April 17, 2018

Funding recipients will address ways to improve shared decision-making and effective health communications.

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.